Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 159 of 5804
-
New drug combo aims to fight untreatable liver cancer
Disease control OngoingThis is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New transplant approach could help more patients with blood disorders
Disease control Recruiting nowHematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs tha…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Feeding kids tiny bits of allergens may help them beat food allergies
Disease control ENROLLING_BY_INVITATIONThe goal of this clinical trial is to learn about oral immunotherapy in food allergic children \< 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Pa…
Phase: NA • Sponsor: Deventer Ziekenhuis • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingPeople with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, giv…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowBackground: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant. Objective: Thi…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New stroke prevention pill could cut risk without extra bleeding
Prevention CompletedResearchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: * an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke),…
Phase: PHASE3 • Sponsor: Bayer • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
Can a cancer drug help flush out hidden HIV?
Disease control Recruiting nowThe purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This …
Phase: PHASE1, PHASE2 • Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a drug combo shrink bile duct tumors before surgery?
Disease control Recruiting nowThis phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab work before surgery in treating participants with Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabin…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized, controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease requiring…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New lung cancer cocktail aims to outperform current standard in phase 3 trial
Disease control OngoingThis is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemothe…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New bladder cancer drug could help patients avoid bladder removal
Disease control OngoingThis is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to…
Phase: PHASE3 • Sponsor: Fidia Farmaceutici s.p.a. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug could save limbs without surgery
Disease control Recruiting nowObjective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.
Phase: PHASE3 • Sponsor: Supergene, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a common gout drug save hearts? colchicine trial targets valve disease
Disease control OngoingAortic stenosis (AS) is the most common valvular heart disease in the developed world. Once symptomatic, untreated patients have a poor prognosis with five-year survival rate of 25%. Once at an advanced stage, AS will lead to the development of left ventricle hypertrophy, and eve…
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 16:46 UTC
-
Could a drug combo free kidney transplant patients from lifelong pills?
Disease control TerminatedThe purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Phase: PHASE2 • Sponsor: ITB-Med LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat head and neck cancers
Disease control CompletedThis study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a f…
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to stall liver cancer progression
Disease control Recruiting nowThe purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy con…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug ALXN1720 aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heated chemotherapy after stomach cancer surgery: a new hope?
Disease control Recruiting nowThe goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving …
Phase: PHASE3 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for hodgkin lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC